A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa
收藏DataCite Commons2025-05-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008738/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This study further evaluates the efficacy of bermekimab in treating moderate to severe
hidradenitis suppurativa in adults. 1/3 of patients will receive weekly injections of
bermekimab, 1/3 will receive alternating every other week injections of bermekimab or
placebo, and 1/3 will receive weekly injections of placebo.
提供机构：
Vivli
创建时间：
2023-01-19
